Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1

Interventions

Carboplatin 63Cisplatin 40Pemetrexed 38Drug Therapy 37osimertinib 23anlotinib 22Etoposide 20tislelizumab 17Radiotherapy 17Paclitaxel 17Surgical Procedures, Operative 16pembrolizumab 15toripalimab 14130-nm albumin-bound paclitaxel 14aflutinib 13Docetaxel 13Bevacizumab 12sintilimab 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Injections 9durvalumab 8cemiplimab 8Radiosurgery 8Platinum 8PM 01183 8Immunotherapy 8atezolizumab 7Platinum Compounds 7Blood Specimen Collection 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × CIMAvax EGF × Thoracic × Clear all
NCT07543172 2026-04-21

CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2 Not yet recruiting
29 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡